Cangrelor Bridge Therapy for Gastroduodenal Biopsy

Area of Science:

• Cardiology
• Pharmacology
• Gastroenterology

Background:

• Dual antiplatelet therapy (DAPT) is essential for secondary prevention in acute coronary syndromes and after coronary stent placement.
• Premature DAPT cessation increases risks of cardiac ischemic events and mortality.
• Bridging therapy is needed for urgent procedures but lacks FDA-approved options.

Observation:

• A patient with a history of gastrointestinal bleeding was on DAPT for a drug-eluting stent.
• The patient required a gastroduodenal biopsy, necessitating a temporary interruption of DAPT.
• Cangrelor was administered as an antiplatelet bridge therapy before the procedure.

Findings:

• Cangrelor served as a bridge therapy in a patient with a history of gastrointestinal bleeding on DAPT.
• This case highlights a potential strategy for managing DAPT interruption in high-risk patients.

Implications:

• Cangrelor may be a viable option for antiplatelet bridging therapy in specific clinical scenarios.
• Further research is needed to establish guidelines for cangrelor use in DAPT bridging.
• Balancing ischemic and bleeding risks remains critical when managing DAPT interruption.